C-Reactive Protein as a Marker of Chronic Inflammation in Uremic Patients

Cardiovascular complications caused by an accelerated atherosclerotic disease represent the largest single cause of mortality in chronic renal failure patients. The rapidly developing atherosclerosis of the uremic syndrome appears to be caused by a synergism of different mechanisms, such as malnutrition, oxidative stress and genetic factors. Recent studies provide evidence that chronic inflammation plays an important role in the pathogenesis of cardiovascular diseases. Elevated serum levels of plasma C-reactive protein (CRP) are associated with an increased risk of experiencing myocardial infarction and sudden cardiac death in apparently healthy subjects. Several recently published papers have confirmed this strong association between CRP and the extent and severity of the atherosclerotic processes. In patients affected by predialytic renal failure, increased levels of CRP and interleukin (IL)-6 were recorded in 25% of our population; CRP and IL-6 were inversely related with renal function. These data suggest the activation – even in the predialytic phase of renal failure – of mechanisms known to contribute to the enhanced cardiovascular morbidity and mortality of the uremic syndrome. In recent years we have investigated the hypothesis that the chronic inflammatory state of the uremic patient could at least in part be due to the dialytic technique. We provide evidence suggesting that the increase of CRP in stable dialytic patients may be due to the stimulation of monocyte/macrophage by backfiltration of dialysate contaminants.

[1]  Ciro Tetta,et al.  Plasma C-Reactive Protein in Hemodialysis Patients: A Cross-Sectional, Longitudinal Clinical Survey1 , 2000, Blood Purification.

[2]  K. Iseki,et al.  Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  C. Visser,et al.  C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? , 1999, Circulation.

[4]  P. Stenvinkel,et al.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.

[5]  T. Ikizler,et al.  Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. , 1999, Kidney international.

[6]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[7]  C. Tetta,et al.  Plasma C-reactive protein is linked to backfiltration associated interleukin-6 production. , 1998, ASAIO journal.

[8]  R H Christenson,et al.  Biochemical markers of the acute coronary syndromes. , 1998, Clinical chemistry.

[9]  C. Tetta,et al.  Cytokine production in haemodiafiltration : a multicentre study , 1998 .

[10]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[11]  A. Maseri Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon. , 1997, The New England journal of medicine.

[12]  J. Bergström,et al.  High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  D. Strachan,et al.  C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.

[14]  M. Haubitz,et al.  Chronic Induction of C-Reactive Protein by Hemodialysis, but Not by Peritoneal Dialysis Therapy , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[15]  G. Shearer,et al.  Mechanisms of hypoalbuminemia in hemodialysis patients. , 1995, Kidney international.

[16]  B. Pereira,et al.  Diffusive and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes. , 1995, Kidney international.

[17]  N. Lameire,et al.  Cardiovascular Risk Factors and Their Management in Patients on Continuous Ambulatory Peritoneal Dialysis , 1994, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[18]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[19]  A. Whitehead,et al.  The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. , 1994, Immunology today.

[20]  M. Nieminen,et al.  Infection and inflammation as risk factors for myocardial infarction. , 1993, European heart journal.

[21]  G. Lonnemann Dialysate bacteriological quality and the permeability of dialyzer membranes to pyrogens. , 1993, Kidney international. Supplement.

[22]  L. Raij,et al.  Cardiovascular risk factors in chronic renal failure and hemodialysis populations. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  B. Descamps-Latscha,et al.  Elevated circulating levels of interleukin-6 in patients with chronic renal failure. , 1991, Kidney international.

[24]  T. Speroff,et al.  Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. , 1991, Journal of immunology.

[25]  I. Kushner,et al.  C-reactive protein and the acute-phase response. , 1990, Hospital practice.

[26]  P. Sehgal,et al.  Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. , 1988, Biochemical and biophysical research communications.

[27]  I. Kushner THE PHENOMENON OF THE ACUTE PHASE RESPONSE * , 1982, Annals of the New York Academy of Sciences.

[28]  B. Scribner,et al.  Accelerated atherosclerosis in prolonged maintenance hemodialysis. , 1974, The New England journal of medicine.

[29]  T. Yoneyama,et al.  Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  M. Goldman,et al.  Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. , 1996, Kidney international.

[31]  G. Shearer,et al.  Mechanisms of hypoalbuminemia in hemodialysis patients (Kidney International 48: (510-516)) , 1995 .

[32]  H. Nakahama,et al.  Plasma interleukin-6 levels in continuous ambulatory peritoneal dialysis and hemodialysis patients. , 1992, Nephron.

[33]  J. Cavaillon,et al.  Serum interleukin-6 in long-term hemodialyzed patients. , 1992, Nephron.

[34]  C. Mold,et al.  C-reactive protein and the acute phase response. , 1982, Advances in internal medicine.